It is widely appreciated that there is significant inter-individual variability in pain sensitivity, yet only a handful of contributing genetic variants have been identified. Computational genetic mapping and quantitative trait locus analysis suggested that variation within the gene coding for the b 3 subunit of the Na + ,K + -ATPase pump (Atp1b3) contributes to inter-strain differences in the early phase formalin pain behavior. Significant strain differences in Atp1b3 gene expression, b 3 protein expression, and biophysical properties of the Na + ,K + pump in dorsal root ganglia neurons from resistant (A/J) and sensitive (C57BL/6J) mouse strains supported the genetic prediction. Furthermore, in vivo siRNA knockdown of the b 3 subunit produced strain-specific changes in the early phase pain response, completely rescuing the strain difference. These findings indicate that the b 3 subunit of the Na + ,K + -ATPase is a novel determinant of nociceptive sensitivity and further supports the notion that pain variability genes can have very selective effects on individual pain modalities. Ó
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Introduction
Identification and characterization of genetic factors responsible for inter-individual variability in pain sensitivity is of critical significance for improving our understanding of pain mechanisms and for developing novel therapies. [24] for review). Some of these genes were obvious candidates and were directly tested in human genetic association studies, whereas others were first identified by genetic analysis of animal models.
There are several reasons for the continuing importance of genetic animal models of pain. First, the inability to control many key variables and to assemble sufficiently powered cohorts has led to failures to demonstrate genetic association with pain phenotypes in humans for many seemingly obvious gene candidates [5] . Second, human genetic association studies have often generated controversial results; different studies examining related pain phenotypes have reported either no association, association with different haplotypes, or directly opposite allelic effects on the pain response [9, 20, 21, 29] . Third, the large number of documented pain-related differences between transgenic knockout mice and their wildtype controls [23] suggests that many more relevant genes have yet to be identified. As of this writing, null mutations in at least 279 murine genes have been associated with an altered pain phenotype, and there are known genetic variants within the human homologues of most of these murine genes.
The formalin test of chemical/inflammatory pain produces wellcharacterized, biphasic recuperative behaviors in rodents [13] . Acute/early phase behaviors are due to direct chemical stimulation of peripheral nociceptors whereas tonic/late phase behaviors are
